Short Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Increases By 19.4%

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 6,880,000 shares, a growth of 19.4% from the January 15th total of 5,760,000 shares. Based on an average daily volume of 2,010,000 shares, the days-to-cover ratio is currently 3.4 days.

Adaptimmune Therapeutics Trading Up 0.3 %

NASDAQ ADAP opened at $0.58 on Friday. Adaptimmune Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.05. The firm has a 50 day moving average of $0.60 and a two-hundred day moving average of $0.81. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $147.90 million, a PE ratio of -2.63 and a beta of 2.42.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ADAP. Two Seas Capital LP purchased a new position in Adaptimmune Therapeutics in the fourth quarter valued at $7,992,000. Long Focus Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after acquiring an additional 7,194,503 shares in the last quarter. Baillie Gifford & Co. increased its holdings in shares of Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after acquiring an additional 1,626,657 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock worth $1,361,000 after acquiring an additional 869,949 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Adaptimmune Therapeutics by 87.7% during the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 152,780 shares during the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Mizuho dropped their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Guggenheim dropped their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Finally, StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $2.79.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.